Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease-Reference-Cited by-同舟云学术

Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease

Published:2024-03 Issue:3 Volume:44 Page:
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Huang Ngan F.¹²³⁴^ORCID,Stern Brett⁵^ORCID,Oropeza Beu P.¹²⁴^ORCID,Zaitseva Tatiana S.⁶,Paukshto Michael V.⁶,Zoldan Janet⁵^ORCID

Affiliation:

1. Department of Cardiothoracic Surgery (N.F.H., B.P.O.), Stanford University, CA.

2. Stanford Cardiovascular Institute (N.F.H., B.P.O.), Stanford University, CA.

3. Department of Chemical Engineering (N.F.H.), Stanford University, CA.

4. Center for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Health Care System, CA (N.F.H., B.P.O.).

5. Department of Biomedical Engineering, The University of Texas at Austin (B.S., J.Z.).

6. Fibralign Corporation, Union City, CA (T.S.Z., M.V.P.).

Abstract

Peripheral artery disease is an atherosclerotic disease associated with limb ischemia that necessitates limb amputation in severe cases. Cell therapies comprised of adult mononuclear or stromal cells have been clinically tested and show moderate benefits. Bioengineering strategies can be applied to modify cell behavior and function in a controllable fashion. Using mechanically tunable or spatially controllable biomaterials, we highlight examples in which biomaterials can increase the survival and function of the transplanted cells to improve their revascularization efficacy in preclinical models. Biomaterials can be used in conjunction with soluble factors or genetic approaches to further modulate the behavior of transplanted cells and the locally implanted tissue environment in vivo. We critically assess the advances in bioengineering strategies such as 3-dimensional bioprinting and immunomodulatory biomaterials that can be applied to the treatment of peripheral artery disease and then discuss the current challenges and future directions in the implementation of bioengineering strategies.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference111 articles.

1. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

2. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis

3. Critical limb ischemia: current challenges and future prospects

4. Critical limb ischemia

5. Molecular regulation of angiogenesis and lymphangiogenesis